Biomind Labs Inc.
BMNDF
Get informed when a big investor buys or sells
+ FollowMarket Cap$35.68M
Close$
$-0.01
102% downside
Current Fair Value
102% downsideOvervalued by 102% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $35.68 Million |
|---|---|
| Enterprise Value | $36.51 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 7.28 |
| Outstanding Shares | 77,571,772 |
Return
| Return on Equity | 76.75% |
|---|---|
| Return on Assets | -4170814.29% |
| Return on Invested Capital | 72.47% |
Valuation & Multiples
| P/E Ratio | -24.47 |
|---|---|
| PEG | -5.04 |
| Price to Sales | - |
| Price to Book Ratio | -0.46 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -26.49 |
| Enterprise Value to Net Income | -26 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | -0.44 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biomind Labs Inc.
5 employees
CEO: Alejandro Antalich Biomind Labs Inc. operates as a biotechnology firm dedicated to advancing innovative pharmaceutical therapies and sophisticated nanotech drug delivery mechanisms, primarily addressing a range of psychiatric and neurological disorders. Am...